← Leaderboards
Guang-Xian Zhang
Thomas Jefferson University
$4,214,777
Attributed
$4,214,777
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $575.3K · FY2009–21$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$4,214,777 · 5
By mechanism
R01$3,218,297 · 2
R21$429,000 · 1
U19$414,525 · 1
R03$152,955 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsChronicTherapeutic EffectAnimal ModelRelapseNeuronsBrainMultiple SclerosisDemyelinationsNeuraxisExperimental Autoimmune EncephalomyelitisInflammationInflammatoryImmunoregulationProductionDisease ProgressionOligodendrogliaMicrogliaPharmaceutical PreparationsIn VivoMacrophageEffective TherapyMyelinationRemyelination
Grant awards (19)
Ursolic acid: a novel oral therapy for chronic stage of MS/EAE by both immunomodulation and neural repair$341,250
R01 · FY2021 · NS · contact PI
Ursolic acid: a novel oral therapy for chronic stage of MS/EAE by both immunomodulation and neural repair$341,250
R01 · FY2020 · NS · contact PI
Ursolic acid: a novel oral therapy for chronic stage of MS/EAE by both immunomodulation and neural repair$341,250
R01 · FY2019 · NS · contact PI
P7C3 as a novel immunomodulator for CNS autoimmunity$195,000
R21 · FY2019 · AI · contact PI
Ursolic acid: a novel oral therapy for chronic stage of MS/EAE by both immunomodulation and neural repair$341,250
R01 · FY2018 · NS · contact PI
P7C3 as a novel immunomodulator for CNS autoimmunity$234,000
R21 · FY2018 · AI · contact PI
Ursolic acid: a novel oral therapy for chronic stage of MS/EAE by both immunomodulation and neural repair$341,250
R01 · FY2017 · NS · contact PI
NSCs produce a triply effective cocktail in the CNS for MS/EAE therapy$305,156
R01 · FY2016 · NS · contact PI
NSCs produce a triply effective cocktail in the CNS for MS/EAE therapy$305,156
R01 · FY2015 · NS · contact PI
NSCs produce a triply effective cocktail in the CNS for MS/EAE therapy$302,104
R01 · FY2014 · NS · contact PI
NSCs produce a triply effective cocktail in the CNS for MS/EAE therapy$294,475
R01 · FY2013 · NS · contact PI
Flow Cytometry/Cell Sorting$84,987
U19 · FY2013 · AI · contact PI
NSCs produce a triply effective cocktail in the CNS for MS/EAE therapy$305,156
R01 · FY2012 · NS · contact PI
Flow Cytometry/Cell Sorting$81,552
U19 · FY2012 · AI · contact PI
Flow Cytometry/Cell Sorting$80,173
U19 · FY2011 · AI · contact PI
Enhance neural stem cell chemoxis toward CNS inflammatory foci in EAE$75,705
R03 · FY2011 · NS · contact PI
Flow Cytometry/Cell Sorting$81,798
U19 · FY2010 · AI · contact PI
Enhance neural stem cell chemoxis toward CNS inflammatory foci in EAE$77,250
R03 · FY2010 · NS · contact PI
Flow Cytometry/Cell Sorting$86,015
U19 · FY2009 · AI · contact PI